Aclarion, Inc. (ACON)
- Previous Close
6.84 - Open
6.92 - Bid 6.44 x 100
- Ask 7.06 x 100
- Day's Range
6.60 - 6.99 - 52 Week Range
6.60 - 3,500.42 - Volume
43,067 - Avg. Volume
220,041 - Market Cap (intraday)
3.902M - Beta (5Y Monthly) 1.08
- PE Ratio (TTM)
-- - EPS (TTM)
-5,151.64 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
11,758.41
Aclarion, Inc. operates as a healthcare technology company in the United States. The company uses magnetic resonance spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments. It develops NOCISCAN software application, a non-invasively analyze the chemical makeup of intervertebral discs in the spine. The company also develops NOCISCAN Post-Processor Suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.
www.aclarion.com5
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: ACON
View MorePerformance Overview: ACON
Trailing total returns as of 4/29/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ACON
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ACON
View MoreValuation Measures
Market Cap
3.99M
Enterprise Value
3.59M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.20
Price/Book (mrq)
4.11
Enterprise Value/Revenue
78.53
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-150.36%
Return on Equity (ttm)
-5,777.80%
Revenue (ttm)
45.72k
Net Income Avi to Common (ttm)
-7.05M
Diluted EPS (ttm)
-5,151.64
Balance Sheet and Cash Flow
Total Cash (mrq)
492.66k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-4.17M